SONOVA HOLDING AG-REG

Sonova’s 2026 AGM shows strong CHF 4.1 bn revenue, a record CHF 4.70 dividend, and new AI‑cochlear investments—highlighting growth in implant markets and future‑focused governance.

Swiss market sees modest dip amid geopolitical tension; Roche‑Nurix deal signals biotech growth and cross‑sector collaboration opportunities.